Recombinant Proteins Market Size – By Products & Services (Products, Production Services), Application (Drug Discovery & Development, Diagnostics, Research), Host-cell (Mammalian Systems, Yeast & Fungi, Bacterial Cells), End-use & Global Forecast, 2024 – 2032

Recombinant Proteins Market Size

Recombinant Proteins Market was valued at USD 2.3 billion in 2023 and is anticipated to witness more than 7.1% CAGR from 2024 to 2032. One of the primary drivers is the increasing demand for biopharmaceuticals and therapeutic proteins, which are essential in the treatment of various diseases such as cancer, diabetes, and autoimmune disorders. Additionally, the growing aging population coupled with rising prevalence of chronic diseases worldwide, is increasing the need for innovative treatment options, further propelling the demand for recombinant proteins.
 

Recombinant proteins are artificially created by combining DNA sequences from two different sources. This is typically done by inserting the desired DNA sequence into a host organism, such as bacteria, yeast, or mammalian cells, which then produce the protein encoded by that sequence. Recombinant proteins are widely used in research, diagnostics, and therapeutics, as they allow to produce large quantities of specific proteins that may be difficult or impossible to isolate from natural sources.
 

Recombinant Proteins Market Trends

• The increasing demand for biopharmaceuticals and therapeutic proteins is a significant driver of the market growth.
   
• Biopharmaceuticals, including therapeutic proteins, are vital in treating various diseases such as cancer, autoimmune disorders, and genetic diseases. Growing demand of biologics and antibody-based therapeutics, drives the demand for recombinant proteins.
   
• For instance, as per the National Institute of Health (NIH), in 2022, U.S. FDA approved fifteen biologics and monoclonal antibodies (mAbs) continued to account for majority of FDA approvals among them. Thus, growing demand for recombinant protein-based therapeutics, is expected to drive the market growth.
   
• Additionally, the rising prevalence of chronic diseases, the growing elderly population, and advancements in biotechnology are all contributing to the increased demand for biopharmaceuticals and therapeutic proteins, further driving the market share.
   

Recombinant Proteins Market Analysis

Based on products & services, the market is segmented into products and production services. The product segment is further segmented into cytokines & growth factors, antibodies, immune checkpoint proteins, virus antigens, enzymes, recombinant regulatory proteins, hormones, and other products. The products segment accounted for over USD 1.5 billion in 2023.
 

• High demand for products can be attributed to the wide range of applications of recombinant proteins across various industries, including pharmaceuticals, biotechnology, and research.
   
• Further, the increasing adoption of biopharmaceuticals, which rely heavily on recombinant proteins aids in market growth.
   
• Additionally, advancements in protein engineering technologies are enabling the production of recombinant protein products with enhanced properties, such as improved stability and bioactivity, further contributing to their market dominance.

Based on application, the recombinant proteins market is segmented into drug discovery & development, research, diagnostics, and other applications. The drug discovery & development segment is further categorized into biologics, vaccines, and cell & gene therapies. The drug discovery & development segment dominated the market with 34.1% of market share in 2023.
 

• Recombinant proteins are essential in drug development processes, including target identification, validation, lead optimization, and preclinical and clinical trials. These proteins are used to study biological processes, evaluate drug candidates, and develop biologics for various therapeutic applications.
   
• The increasing demand for novel and effective therapies, coupled with advancements in biotechnology and protein engineering, is driving the growth of this segment.
   
• Additionally, the growing prevalence of chronic diseases and the increasing demand for personalized medicine have further fueled the demand for recombinant protein therapeutics, further augmenting the segmental growth.
   

Based on host-cells, the recombinant proteins market is categorized into mammalian systems, insect cells, yeast & fungi, bacterial cells, and other host-cells. The mammalian systems segment is predicted to grow at 7% CAGR through 2032.
 

• Mammalian cells hold a prominent position in the market, primarily due to their ability to produce complex proteins that closely mimic human proteins, making them crucial for therapeutic applications.
   
• Additionally, mammalian cells offer high protein yields and can produce large-scale batches, making them suitable for commercial production.
   
• Further, their widespread use in biopharmaceutical research and production has established mammalian cells as a cornerstone in the market.

Based on end-use, the recombinant proteins market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CRO's), and other end-users. The pharmaceutical & biotechnology companies segment is anticipated to reach USD 2.2 billion by 2032.
 

• Pharmaceutical and biotechnology companies hold a significant market share as end-users in the market due to their pivotal role in drug development and research. These companies extensively utilize recombinant proteins in various stages of drug discovery, development, and production.
   
• Additionally, the increasing demand for biologics and personalized medicine further drives the adoption of recombinant proteins by pharmaceutical and biotechnology companies, solidifying their position as key players in this market.

North America recombinant proteins market size surpass USD 1.9 billion by 2032, while depicting a growth rate of 6.9% from 2024 to 2032. The region is home to a robust biotechnology and pharmaceutical industry, fostering innovation and research in protein therapeutics.
 

• Additionally, North America has a well-established healthcare infrastructure and a high prevalence of chronic diseases, driving the demand for recombinant proteins for therapeutic purposes.
   
• Moreover, the presence of leading market players and strong regulatory frameworks further contribute to the region's dominance.
   
• Lastly, increasing investments in research and development, along with a growing focus on personalized medicine in the region, drives the regional market growth.
   

U.S. recombinant proteins market is anticipated to grow at CAGR of 6.8% during the analysis timeframe.
 

• The country's advanced biotechnology and pharmaceutical sectors, coupled with significant investments in R&D, drive innovation and product development in the field of recombinant proteins.
   
• Additionally, a robust ecosystem of biopharmaceutical companies, academic research institutions, and contract manufacturing organizations contributes to the market's growth.
   
• Further, the country's large and diverse patient population, coupled with a well-established healthcare infrastructure and insurance coverage, creates a significant market demand for these therapies, thereby accelerating market growth.
   

Germany has emerged as a key player in the global market for recombinant proteins, showcasing high growth potential.
 

• Factors contributing to this growth include the country's robust biotechnology and pharmaceutical industries, strong research and development capabilities, and a favorable regulatory environment.
   
• Additionally, the increasing prevalence of chronic diseases and the rising demand for biopharmaceuticals are driving the demand for recombinant proteins in Germany.
   

China recombinant proteins market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The country's expanding biopharmaceutical industry supported by favorable government policies is driving demand for recombinant proteins.
   
• Additionally, the rising prevalence of chronic diseases and an aging population in China are increasing the need for advanced biopharmaceuticals, including recombinant proteins, for therapeutic applications.
   
• Furthermore, the growing acceptance and adoption of biologics in the country's healthcare system, coupled with improving healthcare infrastructure and a growing emphasis on personalized medicine, are expected to further boost market growth.
   

South Korea recombinant proteins market is expected to grow significantly over the years.
 

• The country's biopharmaceutical industry has rapidly expanded, fueled by strong government support, a robust research infrastructure, and a skilled workforce.
   
• Further, the country’s strategic focus on biotechnology and pharmaceuticals has led to advancements in recombinant protein production technologies, driving the market's growth.
   
• Additionally, a strong regulatory framework and emphasis on quality control further enhance its appeal as a destination for biopharmaceutical development and manufacturing, positioning South Korea as a key player in the global market.
   

Recombinant Proteins Market Share

The recombinant proteins industry is characterized by intense competition among key players striving to improve patient outcomes and address unmet medical needs. Inorganic growth initiatives such as partnerships, mergers, and acquisitions are common strategies employed by players to expand their market presence, enhance their product portfolios, and gain a competitive advantage.
 

Recombinant Proteins Market Companies

Prominent players operating in the recombinant proteins industry include:

• Abcam Limited
• Abnova Corporation
• Bio-Rad Laboratories, Inc.
• Enzo Life Sciences, Inc.
• GenScript Biotech Corporation
• Merck KGaA
• Proteintech Group, Inc.
• RayBiotech, Inc.
• R&D Systems, Inc.
• Sino Biological, Inc.
• STEMCELL Technologies Inc.
• Thermo Fisher Scientific Inc.
   

Recombinant Proteins Industry News

• In October 2023, Proteintech announced the launch of multi-rAb recombinant secondary antibodies, the newest generation of secondary antibodies. This helped the company to expand its product offerings.
   
• In February 2022, GenScript announced the opening of manufacturing facility in Singapore for highly automated protein and gene preparation services. The state-of-the-art site marks a significant expansion of the company's advanced protein and gene platforms, and is designed to provide high quality, fast turnaround on products required for new vaccines and therapeutics development. This strategy helped the company strengthen its footprint in the Asia Pacific region.
   

This recombinant proteins market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Products & Services

• Products
  • Cytokines & growth factors
    • Interferons (IFNs)
    • Interleukins (ILs)
    • Other cytokines & growth factors
  • Antibodies
  • Immune checkpoint proteins
  • Virus antigens
  • Enzymes
    • Kinases
    • Metabolic enzymes
    • Other enzymes
  • Recombinant regulatory proteins
  • Hormones
  • Other products
• Production services

Market, By Application

• Drug discovery & development
  • Biologics
  • Vaccines
  • Cell & gene therapies
• Research
• Diagnostics
• Other applications

Market, By Host-cell

• Mammalian systems
• Insect cells
• Yeast & fungi
• Bacterial cells
• Other host-cells

Market, By End-use

• Pharmaceutical & biotechnology companies
• Academic & research institutes
• Contract research organizations (CRO's)
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa